Dogwood Therapeutics Seeks Extended Exclusivity with New Halneuron® Patent

Dogwood Therapeutics, Inc., a biotechnology company in its development stage, has filed for new intellectual property protection concerning their synthetic product, Halneuron®. If granted, this new patent could extend exclusivity for Halneuron® until 2045, potentially offering a significant period for commercial exploitation.

According to CEO Greg Duncan, the synthetic process for Halneuron® will be employed during both Phase 3 development and the commercialization stage, promising higher manufacturing yields and reduced costs compared to naturally harvested equivalents. The move is seen as a strategic effort to leverage proprietary manufacturing techniques to maximize market potential over the next two decades.

Halneuron® is currently in Phase 2b and has received fast-track designation by the FDA for treating chemotherapy-induced neuropathic pain (CINP). Its development underscores Dogwood's focus on non-opioid pain treatments.